Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
pharmaceutical investing Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder
pharmaceutical investing Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial
medical device investing Abiomed Announces European Approval (CE Marking) for Impella 5.5 and First Patient Treated at University Heart Center Hamburg
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial
pharmaceutical investing BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema
Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting
Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy
pharmaceutical investing BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii To The Cambodian Government At The Joint Review Committee
Blue Jay Gold Announces Materials Purchase Agreement With Ocean Partners for Remediation Material at Steller
SAGA Metals Completes Diamond Drill Program at the Wolverine Rare Earth Project - All 22 Holes Totalling 3,241 Metres Intersect Prospective REE-Bearing Alteration
